UTHR

United Therapeutics (UTHR) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov^[5], including 3 Phase 3^[1], 2 Phase 2^[2], 2 Phase 1^[3], 1 Phase 4^[4].

Trial NCT05943535^[6] evaluates Placebo in Progressive Pulmonary Fibrosis with a target enrollment of 698 participants. Trial NCT03683186^[7] evaluates Ralinepag in PAH with a target enrollment of 1000 participants. Trial NCT04905693^[8] evaluates Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis with a target enrollment of 1850 participants.

UTHR has 37 Form 4 insider filings recorded at the SEC in the past 30 days^[9].